Компьютерное моделирование активных центров моноаминоксидаз и создание ингибиторов с заданной селективностью
Диссертация
Долгое время разработку новых эффективных ингибиторов МАО сдерживало отсутствие информации о пространственных структурах этих ферментов. Поэтому исследователи с помощью различных экспериментальных методов пытались выявить структурные особенности этих белков: были определены аминокислотные последовательности различных моноаминоксидаз, процентное содержание вторичных структур в белковой глобуле… Читать ещё >
Список литературы
- Белкина Н.В., Скворцов B.C., Иванов A.C., Арчаков А. И. Моделирование трехмерной структуры цитохрома Р450 1А2 и поиск его новых лигандов. // Вопр. мед. химии. 1998. 44. 464−473.
- Веревкина И.В., Аснина В. В., Горкин В. З., Машковский М. Д. Селективное ингибирование пиразидолом моноаминоксидазы типа, А вразличных тканях человека и животных. // Вопр. мед. химии. 1983. 29. 5. 118−123.
- Гловер В., Медведев А. Е. Сандлер М. Изатин: возможная роль в функциональном взаимодействии натрийуретических пептидов и моноаминоксидаз. // Вопр. мед. химии. 1997. 43. 515−521.
- Горкин В.З. Аминоксидазы и их значение в медицине. 1981. М.: Медицина. 333 с.
- Горкин В.З., Медведев А. Е. Моноаминоксидаза. // В кн.: Белки и пептиды. Т. 1. 1995. М.: Наука. 83−89.
- Дубанов A.B., Иванов A.C., Арчаков А. И. Компьютерный поиск новых мишеней для действия противомикробных средств на основе сравнительного анализа геномов. // Вопр. мед. химии. 2001. 47. 353−367.
- Кнолл Дж. История депренила первого селективного ингибитора моноаминоксидазы типа В. // Вопр. мед. химии. 1997. 43. 482−493.
- Крепец В.В., Белкина Н. В., Скворцов B.C., Иванов A.C. Предсказание связывающей способности белок-лигандных комплексов при помощи нелинейных моделей. // Вопр. мед. химии. 2000. 46. 462−473.
- Машковский М.Д. Лекарственные средства. М.: Медицина. 1993. 736 с.
- Медведев А.Е., Типтон К. Ф. Окислительная модификация моноаминокисдаз. // Вопр. мед. химии. 1997. 43. 471−481.
- Позднев В.Ф., Аксенова JI.H., Медведев А. Е. Ингибирование моноаминоксидазы N-алкилоксикарбонил производными этилендиамина. // Биохимия. 2000. 65. 1288−1294.
- Рамсей P.P. Механистические исследования по моноаминоксидазе: значение для МАО, А и МАО В in suti. // Вопр. мед. химии. 1997. 43. 457 470.
- Сингер Т.П., Янковская B.JL, Бернард М., Кронин К., Саблин С. О. Выделение и характеризация эволюционного предшественника моноаминоксидаз, А и Б человека. // Вопр. мед. химии. 1997. 43. 440−456.
- Сквайерс Р.Ф. Открытие форм моноаминоксидаз, А и Б. // Вопр. мед. химии. 1997. 43.433−439.
- Скворцов B.C. Молекулярный докинг при исследовании белок-лигандных комплексов. // Дисс. канд. биол. наук. 1998. 96 с.
- Типтон К.Ф. Ингибиторы моноаминоксидазы и прессорный ответ на пищевые амины. // Вопр. мед. химии. 1997. 43. 6. 494−503.
- Abdel Samed М.М., Akopyan Zh.I., Veryovkina I.V., Kulygina A.A., Gorkin V.Z. Effect of monoamine oxidase inhibitors on qualitative alterations in enzymatic properties of mitochondrial monoamine oxidases. // Biochem. Pharmacol. 1971. 20. 2571−2577.
- Abell C. W., Kwan S.-W. Molecular characterization of monoamine oxidase A and B. // Prog. Nucleic Acid Res. Mol. Biol. 2001. 65. 129−156.
- Abell C.W., Stewart R.M., Andrews P.J., Kwan S.-W. // Heterocycles. 39. 933−955.
- Amzel L.M. Structure-based drug design. // Curr. Opin. Biotechnol. 1998. 9. 366−369.
- Annan N., Silverman R.B. New analogues of N-(2-aminoethyl)-4-chlorobenzamide (Ro 16−6491). Some of the most potent monoamine oxidase-B inactivators. //J. Med. Chem. 1993. 36. 3968−3970.
- Arscott L. D., Williams C.H., Schulz C.E. // In: «Flavins and Flavoproteins» (V. Massey and C.H. Williams, eds.), Elsevier North-Holland, Amsterdam, 1982. pp. 44−48.
- Augen J. The evolving role of information technology in the drug discovery process. // Drug Disc. Today. 2002. 7. 315−323.
- Babine R.E., Bender S.L. Molecular recognition of protein-ligand complexes: applications to drug design. // Chem. Rev. 1997. 97. 1359−1472.
- Baumann K. Uniform-length molecular descriptors for quantitative structure-property relationships (QSPR) and quantitative structure-activity relationships
- QSAR): classification studies and similarity searching. // Trends Anal. Chem. 1999. 18.36−46.
- Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The Protein Data Bank. // Nucl. Acids Res. 2000. 28. 235−242.
- Bernard S., Paillat C., Oddos T., Seman M., Milcent R. Selective and potent monoamine oxidase type B inhibitors: substituted semicarbazones and acylhyrazones of aromatic aldehydes and ketones. // Eur. J. Med. Chem. 1995.30.471−482.
- Berry M.D., Juorio A.V., Paterson I.A. The functional role of monoamine oxidases A and B in the mammalian central nervous system. // Prog.Neurobiol. 1994. 42. 375−391.
- Bianchi P., Seguelas M.H., Parini A., Cambon C. Activation of pro-apoptotic cascade in renal epithelial cells is fully dependent on hydrogen peroxide generation by monoamine oxidases. // J. Am. Soc. Nephrol. 2003. 14. 855 862.
- Binda C., Coda A., Angelini R., Federico R., Ascenzi P., Mattevi A. A 30-angstrom-long U-shaped catalytic tunnel in the crystal structure of polyamine oxidase. // Struct. Fold. Des. 1999. 7. 265−276.
- Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D.E., Mattevi A. Crystal structure of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. // J. Med. Chem. 2004. 47. 1767−1774.
- Binda C., Li M., Hubalek F., Restelli N., Edmondson D.E., Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. // Proc. Natl. Acad. Sci. USA. 2003. 100. 9750−9755.
- Binda C., Newton-Vinson P., Hubalek F., Edmondson D.E., Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. // Nature Struct. Biol. 2002. 9. 22−26.
- Bissantz C., Bernard P., Hibert M., Rognan D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? // Proteins. 2003. 50. 5−25.
- Bissantz C., Folkers G., Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. //J. Med. Chem. 2000. 43. 4759−4767.
- Blanco C., Antia S. X., Liebowitz M. R. Pharmacotherapy of Social Anxiety Disorder. //Biol. Psychiatry. 2002. 51. 109−120.
- Bohm H.J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. //J. Comp.-Aided Mol. Design. 1992. 6. 61−78.
- Boland A., Gerardy J., Mossay D., Seutin V. Pre- and post-treatment with pirlindole and dehydropirindole protects cultured brain cells against nitric oxide-induced death. // Eur. J. Pharmacol. 2003. 466. 21−30.
- Bono P., Salmi M., Smith D. J., Jalkanen, S. Cloning and characterization of mouse vascular adhesion protein-1 (mVAP-1) reveals a novel molecule with enzymatic activity. //J. Immunol. 1998. 160. 5563−5571.
- Boomsma F., de Kam P.J., Tjeerdsma G., van den Meiracker A.H., van Veldhuisen D.J. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. // Eur. Heart J. 2000.21. 1859−1863.
- Borchardt J.K. New Drug Development Costs Now Average $ 802 million. // The Alchemist 6 December 2001. http://www.chemweb.com/alchem/articles/1 005 928 853 806.html.
- Brown G. C. Nitric oxide and mitochondrial respiration. // Biochim. Biophys. Acta. 1999. 1411. 351−369.
- Brown R.D., Martin Y.C. Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection. // J. Chem. Inf. Comp. Sci. 1996. 36. 572−584.
- Bruhlmann C., Ooms F., Carrupt P.A., Testa B., Catto M., Leonetti F., Altomare C., Carotti A. Coumarin derivatives as dual inhibitors of acetylcholinesterases and monoamine oxidase. // J. Med. Chem. 2001. 44. 3195−3198.
- Bruhwyler J., Liegeois J.-F., Geczy J. Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties.// Pharmacol. Res. 1997. 36. 23−33.
- Brunner H.C., Nelen M., Breakefield X.O., Ropers H.H., van Oost B. A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. // Science. 1993. 262. 578−580.
- Bruns C.M., Karplus P.A. Refined crystal structure of spinach ferredoxin reductase at 1.7 A resolution: oxidized, reduced and 2'-phospho-5'-AMP bound states.//J. Mol. Biol. 1995. 247. 125−145.
- Callingham B.A., Holt A., Elliot J. Properties and functions of the semicarbazide-sensitive amine oxidases.// Biochem. Soc. Transact. 1991. 19. 228−233.
- Cambria A., Raudino A., Castelli F., Raciti G., Mazzone P., Buemi G., Pignatello R., Mazzone G. Structure-activity studies on monoamine oxidase inhibitors by calorimetric and quantum mechanical calculations. // J. Enzyme Inhib. 1996. 10.215−229.
- Cesura A.M., Gottowik J., Lang G., Malherbe P., Da Prada M. Structure-function relationships of mitochondrial monoamine oxidase A and B: chimaeric enzymes and site-directed mutagenesis studies.// J. Neural. Transm. 1998. 52(Suppl). 189−200.
- Cesura A.M., Pletscher A. The new generation of monoamine oxidase inhibitors.//Progr. Drug. Res. 1992. 38. 171−297.
- Chen K. Organization of MAO A and MAO B promoters and regulation of gene expression. // Neurotoxicology. 2004. 25. 1−2. 31−36.
- Chen K., Wu H.F., Grimsby J., Shih J.C. Cloning of a novel monoamine oxidase cDNA from trout liver. // Mol. Pharmacol. 1994. 46. 1226−1233.
- Chen K., Wu H.-F., Shih J.C. Influence of C terminus on monoamine oxidase A and B catalytic activity. // J. Neurochem. 1996. 66. 797−803.
- Chiba K., Trevor A.J., Castagnoli N.Jr. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. // Biochem. Biophys. Res. Commun. 1985. 128. 1228−1232.
- Chiba K., Trevor A., Castagnoli N.Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. // Biochem. Biophys. Res. Commun. 1984. 120. 574−578.
- Clark D.E., Pickett S.D. Computational methods for the prediction of «drug-likeness». // Drug Disc. Today. 2000. 5. 49−58.
- Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., Yahr M.D. Pargyline and deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-l, 2,3,6-tetrahydropyridine (MPTP) in monkeys. // Eur. J. Pharmacol. 1984. 106. 209 210.
- Cohen N.C., Blaney J.M., Humblet C., Gund P., Barry D.C. Molecular modeling software and methods for medicinal chemistry. // J. Med. Chem. 1990.33. 883−894.
- Connolly M.L. Analytical Molecular Surface Calculation. // J. Appl. Cryst. 1983. 16. 548−558.
- Correll C.C., Batie C.J. Ballou D.P., Ludwig M.L. Phthalate dioxygenase reductase: a modular structure for electron transfer from pyridine nucleotides to 2Fe-2S. // Science. 1992. 258. 1604−1610.
- Correll C.C., Ludwig M.L., Bruns C.M., Karplus P.A. Structural prototypes for an extended family of flavoprotein reductases: comparison of phthalate dioxygenase reductase with ferredoxin reductase and ferredoxin. // Protein Sei. 1993.2.2112−2133.
- Cramer III R.D., Petterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of share on binding of steroids to carrier proteins. // J. Am. Chem. Soc. 1988, 110, 5959−5967.
- Da Prada M., Kettler R., Keller H.H., Burkland W.P., Haefely W.E. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. // J. Neural. Transm. 1989. 28(SuppI.). 5−20.
- Denney R.M., Fritz R.B., Patel N.T., Widen S.G., Abell C.W. Use of a monoclonal antibody for comparative studies of monoamine oxidase B in mitochondrial extracts of human brain and peripheral tissues. // Mol. Pharmacol. 1983. 24. 60−68.
- Denney R.M., Fritz R.H., Patel N.T., Abell C.W. Human liver MAO-A and MAO-B separated by immunoafflnity chromatography with MAO-B-specific monoclonal antibody.//Science. 1982.215. 1400−1403.
- Denney R.M., Patel N.T., Fritz R.R., Abell C.W. A monoclonal antibody elicited to human platelet monoamine oxidase. Isolation and specificity for human monoamine oxidase B but not A. // Mol. Pharmacol. 1982. 22. 500 508.
- Denney R.M., Sharma A., Dave S.K., Waguespack A. A new look at the promoter of the human monoamine oxidase A gene: mapping transcription initiation sites and capacity to drive luciferase expression. // J. Neurochem. 1994. 63. 843−856.
- Dollery C.T., Brown M.J., Davies D.S., Strolin B.M. // In: Tipton K.F., Dorsert P., Strolin B.M. (eds). Monoamine oxidase and disease. Academic Press, London, 1984. 429−441.
- Domino E.F. Monoamine oxidase, tobacco smoking, and psychiatric disorders. //Biol. Psychiatry. 1996. 40. 433−434.
- Dostert P., Benedetti M.S. Structure-modulated recognition of substrates and inhibitors by monoamine oxidases A and B. // Biochem. Soc. Transact. 1991. 19. 207−211.
- Dostert P., Benedetti M.S., Tipton K.F. Interaction of monoamine oxidase with substrates and inhibitors. // Med. Res. Rev. 1989. 9. 45−89.
- Ebadi M., Srinivasan S.K., Baxi M.D. Oxidative stress and antioxidant therapy in Parkinson’s disease. // Prog. Neurobiol. 1996. 48. 1−19.
- Effect of deprenyl on the progression of disability in early Parkinson’s disease. Parkinson Study Group. New Engl. J. Med. 1989. 321. 1364−1371.
- Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. Parkinson Study Group. New Engl. J. Med. 1993. 328. 176−183.
- Eggink C., Engel H., Vriend C., Terpstra P., Witholt B. Rubredoxin reductase of Pseudomonas oleovorans. Structural relationship to other flavoprotein oxidoreductases based on one NAD and two FAD fingerprints. // J. Mol. Biol. 1990.212. 135−142.
- Ewing T.J.A., Makino S., Skillman A.G., Kuntz I.D. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. // J. Comp.-Aided Mol. Design. 2001. 15. 41128.
- Farren C.K., Clare A.W., Tipton K.F., Dinan T.G. Platelet MAO activity in subtypes of alcoholics and controls in a homogenous population. // J. Psychiatr. Res. 1998. 32. 49−54.
- Feighner J.P. Overview of antidepressants currently used to treat anxiety disorders. // J. Clin. Psychiatry. 1999. 60 (Suppl. 4). 4−11.
- Feighner, J.P. Mechanism of action of antidepressant medications. // J. Clin. Psychiatry. 1999. 60(Suppl. 4). 4−11.
- Fernandes P.B. Technological advances in high-throughput screening. // Curr. Opin. Chem. Biol. 1998. 2. 597−603.
- Fowler J.S., Volkow N.D., Wang C.J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A.P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. // Nature. 1996a. 379. 733−736.
- Fowler J.S., Volkow N.D., Wang C.J., Pappas N., Logan J., Shea C., Alexoff D., MacGregor R.R., Schlyer D.J., Zezulkova I., Wolf A.P. Brain monoamine oxidase A inhibition in cigarette smokers. // Proc. Natl. Acad. Sci. USA. 1996. 93.14 065−14 069.
- Fraaije M.W., Mattevi A. Flavoenzymes: diverse catalysts with recurrent features. //Trends Biochem. Sci. 2000. 25. 126−132.
- Freiberg C. Novel computational methods in anti-microbial target identification. // Drug Disc. Today. 2001. 6. S72-S80.
- Fritz R.R., Abell C.W., Patel N.T., Gessner W., Brossi A. Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B. // FEBS Lett. 1985. 186.224−228.
- Fujita T. Recent success stories leading to commercializable bioactive compound with the aid of traditional QSAR procedures. // QSAR. 1997. 16. 107−112.
- Geha R., Chen K., Shih J. Phe-208 and lie-199 in human monoamine oxidase A and B do not determine substrate and inhibitor specificities as in rat. // J. Neurochem. 2000a. 75. 1304−1309.
- Geha R., Chen K., Shih, J. One corresponding amino acid pair is responsiblefor substrate and inhibitor preference in human monoamine oxidase A and B. th
- In 9 International Amine Oxidase Workshop, The Millenium Meeting. 2000b. Barcelona, P.59.
- Geha R.M., Chen K., Wouters J., Ooms F., Shih J.C. Analisis of conserves active site residues in monoamine oxidase A and B and their three-dimentional molecular modeling. // J. Biol. Chem. 2002. 277. 17 209−17 216.
- Geha R.M., Rebrin I., Chen K., Shih J.C. Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. // J. Biol. Chem. 2001. 276. 9877−9882.
- Ghose A.K., Wendoloski J.J. Pharmacophore modeling: methods, experimental verification and applications. // In «3D QSAR in Drug Design». /Ed. by Kubinyi H. Kluwer Academic Publishers, Great Britain. 1998. 3. 87 104.
- Glover V., Halket J.M., Watkins P.J., Clow A., Goodwin B.L., Sandler M. Isatin: identity with the purified monoamine oxidase inhibitor, tribulin. // J. Neurochem. 1988. 51. 656−659.
- Glover V., Medvedev A., Sandler M. Isatin is a potent endogenous antagonist of guanylate cyclase-coupled atrial natriuretic peptide receptors. // Life Sci. 1995. 57. 2073−2079.
- Glover, V. (1997) in Antidepressants: New Pharmacological Strategies (Skolnick, Ph., ed.) Humana Press, Totowa, NJ, pp. 69−80.
- Goodsell D.S., Morris G.M., Olson A.J. Automated docking of flexible ligands: applications of AutoDock. //J. Mol. Recognit. 1996. 9. 1−5.
- Gorkin V.Z. Monoamine oxidases.//Pharacol. Rev. 1966. 18. 115−120.
- Gorkin V.Z. Qualitative alterations in enzymatic properties of amine oxidases. // Adv. Biochem. Psychopharmacol. 1972. 5. 55−65.
- Gottowik J., Cesura A.M., Malherbe P., Lang C., Da Prada M. Characterisation of wild-type and mutant forms of human monoamine oxidase A and B expressed in a mammalian cell line. // FEBS Lett. 1993. 317. 152 156.
- Gottowik J., Malherbe P., Lang G., Da Prada M., Cesura A. M. Structure/function relationships of mitochondrial monoamine oxidase A and B chimeric forms. //Eur. J. Biochem. 1995. 230. 934−942.
- Grandi T., Sparatore F. Monoamine oxidase inhibitory properties of some benzazoles: Structure-activity relationships.//AAPS Pharmasci. 1999. 1. 1−4.
- Grimsby J., Zentner M., Shih J.C. Identification of a region important for human monoamine oxidase B substrate and inhibitor selectivity. // Life Sci. 1996. 58. 777−787.
- Gurrath M., Muller G., Holtje H.-D. Pseudoreceptor modelling in drug design: application of Yak and PrGen. // In «Perspectives in drug discovery and design."/ Ed. by Anderson P. S., Kenyon G.L., Marshall G.R. 1998. 12/13/14. 135−157.
- Hansch C. Quantitative Structure-Activity Relationships and the Unnamed Science.//Account Chem. Res. 1993.26. 147−153.
- Harfenist M., Joseph D.M., Spence S.C., Mcgee D.P.C., Reeves M.D., White
- H.L. Selective inhibitors of monoamine oxidase. 4. SAR of tricyclic N-methylcarboxamides and congeners at the tricyclics' hydrophilic binding site. // J. Med. Chem. 1997. 40. 2466−2473.
- Harfenist M., Joyner C.T., Mize P.D., White H.L. Selective inhibitors of monoamine oxidase. 2. Arylamide SAR. // J. Med. Chem. 1994. 37. 20 852 089.
- Hasan F., McCrodden J.M., Kennedy N.P., Tipton K.F. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. // J. Neural. Transm. 1988. 26(suppl.). 1−9.
- Hasegawa S., Matsubara K., Takahashi A., Naoi M., Nagatsu T. Inhibition of type A monoamine oxidasre by N-methyl p-carbolinium ions. // Biogenic Amines. 1995. 11. 295−303.
- Hiramatsu A., Tsurushiin S., Yasunobu K.T. Evidence for essential histidine residues in bovine-liver mitochondrial monoamine oxidase. // Eur. J. Biochem. 1975. 57. 587−593.
- Ho B.T., Mclsaac W.M., Walker K.E., Estevez V. Inhibitors of monoamine oxidase. Influence of methyl substitution on the inhibitory activity of beta-carbolines. // J. Pharm. Sci. 1968. 57. 269−274.
- Hoffmann D., Kramer B., Washio T., Steinmetzer T., Rarey M., Lengauer T. Two-stage method for protein-ligand docking. // J. Med. Chem. 1999. 42. 4422−4433.
- Holt A., Berry M.D., Boulton A.A. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. //Neurotoxicology. 2004. 25. 1−2. 251−266.
- Hossain C.F., Okuyama E., Yamazaki M. A new series of coumarin derivatives having monoamine oxidase inhibitory from Monascus anka. // Chem. Pharm. Bull. 1996. 44. 1535−1539.
- Hsu Y.-P.P., Weyler W., Chen S., Sims K.B., Rinehart W.B., Utterback M.C., Powell J.F., Breakefleld X.O. Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. // J. Neurochem. 1988. 51. 1321−1324.
- Hubbard R.E. Can drugs be designed? Curr. Opin. Biotech. 1997. 8. 696−700.
- Husain M., Edmonton D.E., Singer T.P. Kinetic studies on the catalytic mechanism of liver monoamine oxidase. // Biochemistry. 1982. 21. 595−600.
- Hynson R. M, Kelly S. M, Price N. C, Ramsay R.R. Conformational changes in monoamine oxidase A in response to ligand binding or reduction. // Biochim. Biophys. Acta. 2004. 1672. 60−66.
- Hynson R.M.G., Wouters J., Ramsay R.R. Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. // Biochem. Pharmacol. 2003. 65. 1867−1874.
- Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol.1996. 39. 37−45.
- ISIS™/Base: MDL Drug Data Report, Molecular Design Limited Information Systems, Inc., 14 600 Catalina Street, San Leandro, California, 94 577, USA.1997.
- Ito A., Kuwahara T., Inadome S., Sagara Y. Molecular cloning of a cDNA for rat liver monoamine oxidase B. // Biochem. Biophys. Res. Commun. 1988. 157. 970−976.
- Ivanov A.S., Medvedev A.E., Lyulkin Y.A., Skvortsov V.S., Rumjantsev A.B., Gorkin V.Z. Computer modelling of active site of monoamine oxidase A. // In: 14th European workshop on drug metabolism, Paris, France, 4−8 July 1994, 1994, p. 66.
- Jegham S., George P. Monoamine oxidase A and B inhibitors. // Exp.Opin.Ther.Patents. 1998. 8. 1143−1150.
- Jo Y.S., Huong D.T., Bae K., Lee M.K., Kim Y.H. Monoamine oxidase inhibitory coumarin from Zanthoxylum schinifolium. // Planta Med. 2002. 68. 84−85.
- Karplus P.A., Daniels M.J., Herriott J.R. Atomic structure of ferredoxin-NADP+ reductase: prototype for a structurally novel flavoenzyme family. // Science. 1991.251. 60−66.
- Kettmann V., Holtje H.-D. Mapping of the benzothiazepine binding site on the calcium channel. // QSAR. 1998. 17. 91−101.
- Kim H., Sablin S.O., Ramsay R.R. Inhibition of monoamine oxidase A by beta-carboline derivatives. // Arch. Biochem. Biophys. 1997. 337. 137−142.
- Kim J., Fuller J.H., Kuusk V., Cunane L., Chen Z.W., Mathews F.S., Mclntire W.S. The cytochrome subunit is necessary for covalent FAD attachment tothe flavoprotein subunit of p-cresol methylhydroxylase. // J. Biol. Chem. 1995.270.31 202−31 209.
- Kim K.H. Comparative molecular field analysis (CoMFA). // In «Molecular simulation and Drug Design». / Ed. Dean, P.M., Blackie academic & professional, London. 1995. 291−331.
- King L., Parke D.V., Williams R.T. The metabolism of 2−14C. indole in the rat. //Biochem. J. 1966. 98.266−277.
- Kirksey T.J., Kwan S.-W., Abell C.W. Arginine-42 and threonine-45 are required for FAD incorporation and catalytic activity in human monoamine oxidase B. //Biochemistry. 1998. 37. 12 360−12 366.
- Klebe G. Comparative Molecular Similarity Indices: CoMSIA. // In «3D QSAR in Drug Design». / Ed. by Kubinyi H. Kluwer Academic Publishers, Great Britain. 1998. 3. 87−104.
- Kochersperger L.M., Parker E.L., Siciliano M., Darlington G.J., Denney R.M. Assignment of genes for human monoamine oxidases A and B to the X chromosome.//J. Neurosci. Res. 1986. 16. 601−616.
- Krueger M.J., Mazouz F., Ramsay R.R., Milcent R., Singer T.P. Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. // Biochem. Biophys. Res. Commun. 1995. 206. 556−562.
- Kubinyi H. QSAR and Crystallography in Industrial Drug Design. // In «Computer-Aided Drug Design Industrial Research». / Ed. Herrmann E.C., Franke R. Springer Verlag, Berlin. 1995. 99−109.
- Kubinyi H. Variable Selection in QSAR Studies. I. An Evolutionary Algorithm.//QSAR. 1994. 13.285−294.
- Kuntz I.D., Blaney J.M., Oatley S.J., Landridge R., Ferrin T.E. A geometric approach to macromolecule-ligand interactions. // J. Mol. Biol. 1982. 161. 269−288.
- Kuwahara T., Takamoto S., Ito A. Primary structure of rat monoamine oxidase A deduced from cDNA and its expression in rat tissues. // Agric. Biol. Chem. 1990. 54. 253−257.
- Kwan S.-W. Abell C.W. cDNA cloning and sequencing of rat monoamine oxidase A: comparison with the human and bovine enzymes. // Comp. Biochem. Physiol. 1992. 102B, 143−147.
- Kwan S.-W., Bergeron J.M., Abell C.W. Molecular properties of monoamine oxidase. // Psichofarmacology. 1992. 106. 1−5.
- Kwan S.-W., Lewis D.A., Zhou B.P., Abell C.W. Characterization of a dinucleotide-binding site in monoamine oxidase B by site-directed mutagenesis. // Arch. Biochem. Biophys. 1995. 316. 385−391.
- Lan N.C., Heinzmann C., Gal A., Klisak I., Orth U., Lai E., Grimsby J., Sparkes R.S., Mohandas T., Shih J.C. Human monoamine oxidase A and B genes map to Xp 11.23 and are deleted in a patient with Norrie disease. // Genomics. 1989. 4. 552−559.
- Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. // Science. 1983. 219. 979−980.
- Langston J.W., Irwin I., Langston E.B., Forno L.S. Pargyline prevents MPTP-induced parkinsonism in primates. // Science. 1984. 225. 1480−1482.
- Lawrence M.C., David P.C. CLIX: a search algorithm for finding novel ligands capable of binding protein of known three-dimensional structure. // Proteins. 1992. 12.31−41.
- Lebreton L., Curet O., Gueddari S., Mazouz F., Bernard S., Burstein C., Milcent R. Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives. // J. Med. Chem. 1995. 38. 4786−4792.
- Levant B. Novel drug interactions at D (2) dopamine receptors: modulation of 3H. quinpirole binding by monoamine oxidase inhibitors. // Life Sci. 2002. 71.2691−2700.
- Levitt P., Pintar J.E., Breakfield X.O. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. // Proc. Natl. Acad. Sci. USA. 1982. 79. 6385−6389.
- Levy E.R., Powell J.F., Buckle V.J., Hsu Y.-P.P., Breakefield X.O., Craig I.W. Localization of human monoamine oxidase-A gene to Xpl 1.23−11.4 by in situ hybridization: implications for Norrie disease. // Genomics. 1989. 5. 368−370.
- Liu K.J., Grinstaff M.W., Jiang J., Suslick K.S., Swartz H.M., Wang W. In vivo measurement of oxygen concentration using sonochemically synthesized microspheres. 11 Biophys. J. 1994. 67. 896−901.
- Lohse M.J. The future of pharmacology // Trends Pharmacol. Sci. 1998. 19. 198−200.
- Lu G., Campbell W.H., Schneider G., Lindqvist Y. Crystal structure of the FAD-containing fragment of corn nitrate reductase at 2.5 A resolution: relationship to other flavoprotein reductases. // Structure. 1994. 2.809−821.
- Lu X., Silverman R.B. Inactivation of Monoamine Oxidase B by cis- and trans-5-Aminomethyl-3-(4-methoxyphenyl)dihydrofuran-2(3H)-ones. // Bioorg. Med. Chem. 1998. 6. 1851−1856.
- Luque J.M., Kwan S.-W., Abell C.W., Da Prada M., Richards J.C. Cellular expression of mRNAs encoding monoamine oxidases A and B in the rat central nervous system. // J. Comp. Neurol. 1995. 363. 665−680.
- Lyles G.A. Mammalian plasma and tissue-bond semicarbazide-sensitive amine oxidases: Biochemical, pharmacological and toxicological aspects. // Int. J. Biochem. Cell. Biol. 1996. 28. 259−274.
- Ma J., Yoshimura M., Yamashita E., Nakagawa A., Ito A., Tsukihara T. Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. // J. Mol. Biol. 2004b. 338. 103−114.
- Manallack D.T., Livingstone D.J. Neural networks in drug discovery: have they lived up to their promise? // Eur. J. Med. Chem. 1999. 34. 195−208.
- Maret G., Tayar N.E., Carrupt P.-A., Testa B., Jenner P., Baird M. Toxication of MPTP (l-Metil-4-Phenil-l, 2,3,6,-Tetrahydropyridine) and Analogs by Monoamine Oxidase. A Structure-Reactivity Relationship Study. // Biochem. Pharmacol. 1990. 40. 783−792.
- Marrone T.J., Briggs J.M., McCammon J.A. Structure-Based Drug Design: Computational Advances. // Annu. Rev. Pharmacol. Toxicol. 1997. 37. 7190.
- Massey V., Curti B. A new method of preparation of D-amino acid oxidase apoprotein and a conformational change after its combination with flavin adenine dinucleotide. // J. Biol. Chem. 1966. 241. 3417−3423.
- May T., Rommelspacher H., Pawlik M. 3H. harman binding experiments. I: A reversible and selective radioligand for monoamine oxidase subtype A in the CNS of the rat. // J. Neurochem. 1991. 56. 490−499.
- Medevedev A.E., Gorkin V.Z. Endogenous stimulation of lipid peroxidation in brain increases proteolytic inactivation of mitochondrial monoamine oxidases.//Int. J. Devel. Neurosci. 1994. 12. 151−155.
- Medvedev A., Bussygina O., Pyatakova N., Glover V., Severina I.S. Effect of isatin on nitric oxide-stimulated soluble guanylate cyclase from human platelets. // Biochem. Pharmacol., 2002. 63. 763−766.
- Medvedev A.E., Abakumova O.Yu., Podobed O.V., Tsvetkova T.A., Sandler M., Glover V. Effects of isatin on atrial natriuretic peptide-mediated accumulation of cGMP and guanylyl cyclase activity of PC 12 cells. Life Sei. 2001.69. 1783−1790.
- Medvedev A.E., Glover V. Tribulin and endogenous MAO-inhibitory regulation in vivo. //Neurotoxicology. 2004. 25. 1−2. 185−192.
- Medvedev A.E., Kirkel A.A., Kamyshanskaya N.S., Moskvitina T.A., Axenova L.N., Gorkin V.Z., Andreeva N.I., Golovina S.M., Mashkovsky M.D. Monoamine oxidase inhibition by novel antidepressant tertindole. // Biochem. Pharmacol. 1994. 47. 303−308.
- Medvedev A.E., Kirkel A.Z., Kamyshanskaya N.S., Gorkin V.Z. Lipid peroxidation affects catalytic properties of rat liver mitochondrial monoamine oxidases and their sensitivity to proteolysis. // Int. J. Biochem. 1993. 25. 1791−1799.
- Medvedev A.E., Shedov V.l., Chulkova T.M., Fedotova O.A., Saederup E., Squires R.F. Effects of the antidepressant pirindole and its dehydroderivative on the activity of monoamine oxidase-A and on GABAa receptors. // Neurochem. Res. 1996.21. 1521−1526.
- Meng E.C., Kuntz I.D., Abraham D.J., Kellog G.E. Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities. // J.Comp.-Aided Mol. Design. 1994. 8. P.299−306.
- Meng E.C., Shoichet B.K., Kuntz I.D. Automated Docking with Grid-Based Energy Evaluation. // J. Comp. Chem. 1992. 13. 505−524.
- Minamiura N., Yasunobu K.T. Bovine liver monoamine oxidase. A modified purification procedure and preliminary evidence for two subunits and one FAD. //Arch. Biochem. Biophys. 1978. 189. 481−489.
- Mitoma J.-Y., Ito A. The carboxy-terminal 10 amino acid residues of cytochrome b5 are necessary for its targeting to the endoplasmic reticulum. // EMBO J. 1992. 11.4197−4203.
- Morens D.M., Grandinetti A., Reed D., White L.R., Ross C.W. Cigarette smoking and protection from Parkinson’s disease: false association or etiologic clue?//Neurology. 1995.45. 1041−1051.
- Moriguchi I., Hirono S., Nakagome I. Comparison of reliability of logP values for drugs calculated by several methods. // Chem. Pharm. Bull. 1994. 42. 976−978.
- Myers P.L. Will combinatorial chemistry deliver real medicines? // Curr. Opin. Biotech. 1997. 8. 701−707.
- Nicotra A., Pierucci F., Parvez H., Senatori O. Monoamine oxidase expression during development and aging. // Neurotoxicology. 2004. 25. 1−2. 155−166.
- Norinder U. The Advantages of Using Rational Drug Design in Modern Drug Discovery: How to Integrate Computer-Aided Drug Design and Modern
- Biotechnology. // In «Computer-Aided Drug Design Industrial Research». / Ed. Herrmann E.C., Franke R. Springer Verlag, Berlin. 1995. 99−109.
- O’Sullivan J., Unzeta M., Healy J., O’Sullivan M/I., Davey G., Tipton K.F. Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do. // Neurotoxicology. 2004. 25. 1−2. 303−316.
- Ooms F. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. // Curr. Med. Chem. 2000. 7. 141 158.
- Oprea T.I., Marshall G.R. Receptor-based prediction of binding affinities. // In «Perspectives in drug discovery and design.» Ed. Anderson P. S., Kenyon G.L., Marshall G.R. 1998. 09/10/11. 35−61.
- Oreland L. Purification and properties of pig liver mitochondrial monoamine oxidase. // Arch. Biochem. Biophys. 1971. 146. 410−421.
- Otto A., Stoltz M., Sailer H.P., Brandsch R., Biogenesis of the covalently flavinylated mitochondrial enzyme dimethylglycine dehydrogenase. // J. Biol. Chem. 1996. 271. 9823−9829.
- Packman L.C., Mewies M., Scrutton N.S. The flavinylation reaction of trimethylamine dehydrogenase. Analysis by directed mutagenesis and electrospray mass spectrometry. // J. Biol. Chem. 1995. 270. 13 186−13 191.
- Palmer S.L., Mabic S., and Castagnoli N. Jr. Probing the active sites of monoamine oxidase A and B with 1,4-disubstituted tetrahydropyridine substrates and inactivators. // J. Med. Chem. 1997. 40. 1982−1989.
- Panova N.G., Zemskova M.A., Axenova L.N., Medvedev A.E. Does isatin interact with rat brain monoamine oxidases in vivo? // Neurosci. Lett. 1997. 233. 58−60.
- Pawelek P.D., Cheah J., Coulombe R., Macheroux P., Ghisla S., Vrielink A. The structure of L-amino acid oxidase reveals the substrate trajectory into an enantiomerically conserved active site. // EMBO J. 2000. 19. 4204−4215.
- Petzer J.P., Steyn S., Castagnoli K.P., Chen J.F., Schwarzschild M.A., Van der Schyf C.J., Castagnoli N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. // Bioorg. Med. Chem. 2003. 11. 12 991 310.
- Pintar J.E., Barbosa J., Francke U., Castiglione C.M.Jr., Hawkins M., Breakefield X.O. Gene for monoamine oxidase type A assigned to the human X chromosome.//J. Neurosci. 1981. 1. 166−175.
- Ponec R, Amat L, Carbo-Dorca R Molecular basis of quantitative structure-properties relationships (QSPR): a quantum similarity approach. // J. Comp.-Aided Mol. Des. 1999. 13. 259−270.
- Poroikov V.V., Filimonov D.A. How to acquire new biological activities in old compounds by computer prediction. // J. Comp.-Aided Mol. Des. 2002. 16. 819−824.
- Poroikov, V.V.- Filimonov, D.A.- Borodina, Yu.V.- Lagunin, A.A.- Kos, A. Robustness of biological activity predicting by computer program PASS for noncongeneric sets of chemical compounds. // J. Chem. Inf. Comput. Sci. 2000. 40. 1349−1355.
- Poulos T.L., Finzel B.C., Howard A.J. High-resolution crystal structure of cytochrome P450cam. // J. Mol. Biol. 1987. 195. 687−700.
- Prosser R.S., Luchette P.A., Westerman P.W., Rozek A., Hancock R.E. Determination of membrane immersion depth with 0(2): a high-pressure (19)F NMR study. // Biophys. J. 2001. 80. 1406−1416.
- Ramsay R., Tan A.K., Weyler W. Kinetic properties of cloned human liver monoamine oxidase A. // J. Neural. Trans. 1994. 41(Suppl.). 17−26.
- Ramsay R.R., Hunter D.J.B. Inhibitors alter the spectrum and redox properties of monoamine oxidase A. // Biochim. Biophys. Acta. 2002. 1601. 178−184.
- Ramsay R.R., Sablin S.O. A second redox group in monoamine oxidase: its role in catalysis and inhibition. // Neurobiology. 1999. 7. 205−212.
- Ramsay R.R., Singer T.P. The kinetic mechanisms of monoamine oxidases A andB. //Biochem. Soc. Transact. 1991. 19. 219−223.
- Rarey M, Wefing S, Lengauer T. Placement of medium-sized molecular fragments into active sites of proteins. // J. Comp.-Aided Mol. Des. 1996. 10. 41−54.
- Riley L.A., Waguespack M.A., Denney R.M. Characterization and quantitation of monoamine oxidases A and B in mitochondria from human placenta. // Mol. Pharmacol. 1989. 36. 54−60.
- Robinson K.M., Lemire B.D. A requirement for matrix processing peptidase but not for mitochondrial chaperonin in the covalent attachment of FAD to the yeast succinate dehydrogenase flavoprotein. // J. Biol. Chem. 1996. 271. 4055−4060.
- Rommelspacher H., May T., Salewski B. Harman (1-methyl-beta-carboline) is a natural inhibitor of monoamine oxidase type A in rats. // Eur. J. Pharmacol. 1994. 252. 51−59.
- Sablin S.O., Ramsay R.R. Monoamine oxidase contains a redox-active disulfide. // J. Biol. Chem. 1998. 273. 14 074−14 076.
- Sagin F.G., Sozmen E.Y., Ersoz B., Mentes G. Link between monoamine oxidase and nitric oxide. // Neurotoxicology. 2004. 25. 1−2. 91−100.
- Salach J.I. Monoamine oxidase from beef liver mitochondria: simplified isolation procedure, properties, and determination of its cysteinyl flavin content.//Arch. Biochem. Biophys. 1979. 192. 128−137.
- Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. // Amer. J. Psychiat. 1965. 122. 509−522.
- Schilling B., Lerch K. Amine oxidase from Aspergillus niger: Identification of the a novel flavin-dependent enzyme. // Biochim. Biophys. Acta. 1995. V.1243. P.529−537.
- Schleifer K.-J. Pseudoreceptor model for ryanodine derivatives at calcium release channels. // J. Comp.-Aided Mol. Des. 2000. 14. 467−475.
- Schneider G., Bohm H-J. Virtual screening and fast automated docking methods. // Drug Disc. Today. 2002. 7. 64−70.
- Schoichet B.K., Kuntz I.D. Matching chemistry and shape in molecular docking. // Protein Eng. 1993. 6. 723−732.
- Shih J.C. Cloning, after cloning, knock-out mice, and physiological functions of MAO A and B. // Neurotoxicology. 2004. 25. 1−2. 21−30.
- Shih J.C., Grimsby J., Chen K., Zhu Q.S. Structure and promoter organization of the human monoamine oxidase A and B genes. // J. Psychiatry Neurosci. 1993. 18.25−32.
- Shih J.C., Zhu Q.S., Grimsby J., Chen K. Identification of human monoamine oxidase (MAO) A and B gene promoters. // J. Neural. Transm. 1994. 41(Suppl.). 27−33.
- Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: from genes to behavior. // Annu. Rev. Neurosci. 1999. 22. 197−217.
- Shiloff B.A., Behrens P.Q., Kwan S.-W., Lee J.H., Abell C.W. Monoamine oxidase B isolated from bovine liver exists as large oligomeric complexes in vitro. // Eur. J. Biochem. 1996. 242. 41−50.
- Silverman R.B. The use of mechanism-based inactivators to probe the mechanism of monoamine oxidase. // Biochem. Soc. Transact 1991. 19. 201 206.
- Silvestri R., La Regina G., De Martino G., Artico M., Befani O., Palumbo M., Agostinelli E., Turini P. Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B. // J. Med. Chem. 2003. 46. 917−920.
- Silvestri R., La Regina G., De Martino G., Artico M., Befani O., Palumbo M., Agostinelli E., Turini P. Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B. // J. Med. Chem. 2003. 46. 917−920.
- Singer T.P. Inhibitors of FAD-Containing Monoamine Oxidases. // In «Structure and functions of amine oxidase». / Ed. Mondovi B., Boca Raton. Florida. 1985.219−230.
- Singer T.P., Salach J.I., Castagnoli N.Jr., Trevor A. Interactions of the neurotoxic amine, MPTP, with monoamine oxidases. // Biochem. J. 1986. 235. 785−789.
- Singer T.P., Salach J.I., Crabtree D. Reversible inhibition and mechanism-based inhibition of monoamine oxidase by MPTP. // Biochem. Biophys. Res. Commun. 1985. 127. 707−712.
- Sippl W. Receptor-based 3D QSAR analysis of estrogen receptor ligands — merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. // J. Comp.-Aided Mol. Des. 2000. 14. 559−572.
- Sippl W., Contreras J.-M., Parrot I., Rival Y.M., Wermuth C.G. Structure-based 3D QSAR and design of novel acetylcholineesterase inhibitors. // J. Comp.-Aided Mol. Des. 2001. 1., 395−410.
- Skulachev V.P. Power transmission along biological membranes. // J. Membr. Biol. 1990. 114. 97−112.
- Spaltmann F., Blunck M., Ziegelbauer K. Computer-aided target selection -prioritizing targets for antifungal drug discovery. // Drug Disc. Today. 1999. 4. 17−26.
- Sybyl 6.8, Tripos Inc., 1699 South Hanley Road, St Louis, Missouri, 63 144, USA.
- Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. // Science. 1989. 245. 519−522.
- Thibaut U. Application of CoMFA and related 3D QSAR approaches. // In: 3D-QSAR in drug design: Theory, methods, and application. / Ed. Kubinyi, H. ESCOM, Leiden, The Netherland, 1993. 661−696.
- Thomas T., McLendon C., Thomas G. L-deprenyl: nitric oxide production and dilation of cerebral blood vessels. // Neuroreport. 1998. 9. 2595−2600.
- Thorpe L. W., Westlund K. N., Kochersperger L. M., Abell C. W., Denney R. M. Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. // J. Histochem. Cytochem. 1987. 35, 2332.
- Thull U., Kneubuhler S., Gaillard P., Carrupt P.-A., Testa B., Altomare C., Carotti A., Jenner P., McNaught K., St.P. Inhibition of Monoamine Oxidase by Isoquinoline Derivatives. // Biochem. Pharmacol. 1995. 50. 869−877.
- Tipton K. F. Inhibitors of monoamine oxidase and the pressor response to dietary amines. // In: Milestones in monoamine oxidase research: discovery of (-)deprenyl (K.Magyar and E.S.Visi eds.) Meditcina Publishing House Co., Budapest, 2000, pp. 19−32.
- Tipton K.F. // In: Biochemical and pharmacological aspects of depression. Tipton K.F., Youdim M.B.H. (eds.) Taylor & Francis, London, 1989. 193 203.
- Tipton K.F., O’Carroll A.-M., McCrodden J.M. The catalytic behaviour of monoamine oxidase. // J. Neural. Transm. 1987. 43(Suppl.). 25−35.
- Trevor A.J., Singer T.P., Ramsay R.R., and Castagnoli N.Jr. Processing of MPTP by monoamine oxidases: implications for molecular toxicology. // J. Neural Transm. 1987. 23(Suppl.). 73−89.
- Tsugeno Y. Ito A. A key amino acid responsible for substrate selectivity of monoamine oxidase A and B. // J. Biol. Chem. 1997. 272. 14 033−14 036.
- Tsugeno Y., Hirashiki I., Ogata F., Ito A. Regions of the molecule responsible for substrate specificity of monoamine oxidase A and B: A chimeric enzyme analysis. // J. Biochem. 1995. 118. 974−980.
- Vetulani J., Nalepa I. Antidepressants: past, present and future. // Eur. J. Pharmacol., 2000. 405. 351−363.
- Violette S.M., Shakespeare W.C., Bartlett C., Guan W., Smith J.A., Rickles R.J., Bohacek R.S., Holt D.A., Baron R., Sawyer T.K. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. // Chem. Biol. 2000. 7. 225−235.
- Waldmeier P.C. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). // J. Neural. Transm. 1987. 23(Suppl.). 55−72.
- Walker M.C., Edmondson D.E. Structure-activity relationships in the oxidation of benzylamine analogues by bovine liver mitochondrial monoamine oxidase B. // Biochemistry. 1994. 33. 7088−7098.
- Walker W.H., Kearney E.B., Seng R., Singer T.P. The covalently-bound flavin of hepatic monoamine oxidase. 2. Identification and properties of cysteinyl riboflavin. // Eur. J. Biochem. 1971. 24. 328−331.
- Way JC. 2000. Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs. // Curr. Opin. Chem. Biol. 4. 40−46.
- Weber H.P. Screening three-dimensional databases for lead finding. // In «Computer-Aided Drug Design Industrial Research."/ Ed. Herrmann E.C., Franke R. Springer Verlag. Berlin. 1995. 111−128.
- Weinstock M., Poltyrev T., Bejar C., Youdim M.B.H. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. // Psychopharmacology. 2002. 160. 318−324.
- Westlund K.N., Denney R.M., Kochersperger L.M., Rose R.M., Abell C.W. Distinct monoamine oxidase A and B populations in primate brain. // Science. 1985.230. 181−183.
- Westlund K.N., Denney H.M., Rose R.M., Abell C.W. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. //Neuroscience. 1988. 25. 439−456.
- Weyer W., Hsu Y.-P.P., Breakefield X.O. Biochemistry and genetics of monoamine oxidase. // Pharmac. Ther. 1990. 47. 391−417
- Weyler W. Functional expression of C-terminally truncated human monoamine oxidase type A in Saccharomyces cerevisiae. // J. Neural Transm. 1994. 41(suppl.). 3−15.
- Weyler W. Monoamine oxidase A from human placenta and monoamine oxidase B from bovine liver both have one FAD per subunit. // Biochem. J. 1989. 260. 725−729.
- Wierenga R.K., Terpstra P., Hoi W.G.J. Prediction of the occurrence of the ADP-binding beta alpha beta-fold in proteins, using an amino acid sequence fingerprint.//J. Mol. Biol. 1986/ 187. 101−107.
- Wiesner R., Kasuschke A., Kuhn H., Anton M., Schewe T. Oxygenation of mitochondrial membranes by the reticulocyte lipoxygenase. Action on monoamine oxidase activities A and B. // Biochim. Biophys. Acta. 1989. 986. 11−17.
- Windrem D.A., Plachy W.Z. The diffusion-solubility of oxygen in lipid bilayers. // Biochim. Biophys. Acta. 1980.600. 655−665.
- Wlodawer A., Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. // Annu. Rev. Biophys. Biomol. Struct. 1998. 27. 249−284.
- Wouters J. Structural aspects of monoamine oxidase and its reversible inhibition. // Curr. Med. Chem. 1998. 5. 137−162.
- Wouters J., Baudoux G. First partial three-dimensional model of human monoamine oxidase A. // Proteins: Structure, Function, and Genetics. 1998. 32. 97−110.
- Wouters J., Durant F., Champagne B., Andre J.M. Electronic properties of flavins: implications on the reactivity and absorption properties of flavoproteins. //Int. J. Quant. Chem. 1997. 64. 721−733.
- Wu H.-F., Chen K., Shih J.C. Site-directed mutagenesis of monoamine oxidase A and B: role of cysteines. // Mol. Pharmacol. 1993. 43. 888−893.
- Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004. 25. 215−221,
- Yoshimi K., Kozuka M., Sakai J., Iizawa T., Shimizu Y., Kaneko I., Kojima K., Iwata N. Novel Monoamine Oxidase Inhibitors, 3-(2-Aminoethoxy)-l, 2-benzisoxazole Derivatives, and Their Differential Reversibility. // Jpn. J. Pharmacol. 2002. 88. 174 182.
- Youdim M.B.H., Finberg J.P.M. New directions in monoamine oxidase A and B selective inhibitors and substrates. // Biochem. Pharmacol. 1991. 41. 155 162.
- Youdim M.B.H., Narshak N., Yoshioka M., Araki H., Mukai Y., Gotto G. Novel substrates and products of amine oxidase-catalysed reactions. // Biochem. Soc. Transact. 1991. 19. 224−228.
- Youdim M.B.H., Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. // Neurotoxicology. 2004. 25. 1−2. 243−250.
- Zbinden P., Dobler M., Folkers G., Vedani A. PrGen: pseudoreceptor modeling using receptor-mediated ligand alignment and pharmacophore equilibration.//QSAR. 1998. 17. 122−129.
- Zeng J. Mini-review: computational structure-based design of inhibitors that target protein surfaces. // Comb. Chem. High Throughput Screen. 2000. 3. 355−362.
- Zhong B., Silverman R. B. Identification of the active site cysteine in bovine liver monoamine oxidase B. // J. Am. Chem. Soc. 1997. 119. 6690−6691.
- Zhou B.P., Lewis D.A., Kwan S.-W., Kirksey T.J., Abell C.W. Mutagenesis at a highly conserved tyrosine in monoamine oxidase B affects FAD incorporation and catalytic activity. //Biochemistry. 1995. 34. 9526−9531.
- Zhou B.P., Wu B., Kwan S.-W., Abell C.W. Characterization of a highly conserved FAD-binding site in human monoamine oxidase B. // J. Biol. Chem. 1998.273. 14 862−14 868.
- Zhu Q.S., Grimsby J., Chen K., Shih J.C. Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. // Neurosci. 1992. 12. 4437−4446.
- Zutshi R, Chmielewski J. 2000. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. // Bioorg. Med. Chem. Lett. 10. 1901−1903.1. Благодарности
- Автор выражает искреннюю признательность своему консультанту (проф., д.б.н. Медведеву А.Е.) за многолетнее плодотворное сотрудничество, за внимание и ценные критические замечания при написании данной работы.
- Выражаю благодарность проф. K. Tipton (Ireland), проф. Rona Ramsay (Scottland) и д-ру JohanWouters (Belgium) за полезные советы и дискуссии.
- Выражаю признательность всем сотрудникам лаборатории молекулярно-графического конструирования лекарств ГУ НИИ БМХ РАМН за всестороннюю поддержку при выполнении данной работы. Хочется поблагодарить к.б.н. О. В. Тихонову за совместную плодотворную работу.
- Автор выражает благодарность за финансовую поддержку работы РФФИ (гранты 99−04−48 822, 01−04−48 128 и 03−04−48 244) и 1ЫТА8 (грант 99−433).